{"schema_version":"1","generated_at":"2026-10-28T14:01:19.252Z","data_as_of":null,"url":"https://www.findmykol.com/kol/sabarish-ayyappan","json_url":"https://www.findmykol.com/kol/sabarish-ayyappan/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"sabarish-ayyappan","name":"Sabarish Ayyappan","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"University of Iowa","institution_url":"https://www.findmykol.com/institution/university-of-iowa","city":"Iowa City","state":"IA","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1558551507","orcid":"0000-0001-6451-7795","openalex":"A5015875316"},"summary":"Sabarish Ayyappan is a Hematology physician affiliated with University of Iowa. OpenAlex indexes 89 publications with 891 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":89,"cited_by_count":891,"h_index":15,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00305799","title":"Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors","status":"COMPLETED","role":"Overall official","sponsor":"Case Comprehensive Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT00305799","trial_url":"https://www.findmykol.com/trial/NCT00305799"}],"source":"trials"},"payments":{"company_count":36,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1558551507","source":"payments"},"prescribing":{"data_year":2023,"areas_total":6,"areas_shown":3,"areas":[{"area":"Dermatology","share_pct":37.3,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":37.3,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":31}]},{"area":"Metabolism & gastrointestinal","share_pct":26.6,"classes_total":4,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":11.4,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":14},{"class":"Proton pump inhibitor","setting":"prescribed","share_pct":6.8,"drugs":[{"name":"Omeprazole","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":15.9,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":10.7,"drugs":[{"name":"Calquence","share_pct":63.6},{"name":"Brukinsa","share_pct":36.4}],"max_beneficiaries":null},{"class":"BCL-2 Inhibitor","setting":"prescribed","share_pct":5.2,"drugs":[{"name":"Venclexta","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","year":2025,"journal":"Nature Cancer","source_url":"https://doi.org/10.1038/s43018-025-00921-6","status":"verified"},{"title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers","year":2025,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-025-01257-1","status":"verified"},{"title":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2025018527","status":"verified"},{"title":"SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance","year":2025,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/j.clml.2025.04.006","status":"verified"},{"title":"Defining primary refractory large B-cell lymphoma","year":2024,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024012760","status":"verified"}],"source":"works"},"similar":[{"name":"Lawrence Hunsicker","slug":"lawrence-hunsicker","institution":"University of Iowa","specialty":"Nephrology","url":"https://www.findmykol.com/kol/lawrence-hunsicker","json_url":"https://www.findmykol.com/kol/lawrence-hunsicker/profile.json"},{"name":"Brian Olshansky","slug":"brian-olshansky","institution":"University of Iowa","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/brian-olshansky","json_url":"https://www.findmykol.com/kol/brian-olshansky/profile.json"},{"name":"Robert Weiss","slug":"robert-weiss","institution":"University of Iowa","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/robert-weiss","json_url":"https://www.findmykol.com/kol/robert-weiss/profile.json"},{"name":"Carla Nester","slug":"carla-nester","institution":"University of Iowa","specialty":"Pediatric Nephrology","url":"https://www.findmykol.com/kol/carla-nester","json_url":"https://www.findmykol.com/kol/carla-nester/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}